Trial argues strongly for the development of 1st-line biomarker selected strategies in pancreatic ductal adenocarcinoma

Durvalumab plus bevacizumab, added to TACE, shows benefit for unresectable hepatocellular carcinoma

Part 6: Which different PARP inhibitors are available

Part 7: Similarities and Differences

Part 8: How PARP inhibitors are being used now

Part 9: What PARP inhibitors mean for the future and what to look out for

Psilocybin-assisted psychotherapy for cancer-related anxiety and depression

Sudan: Conflict, cancer care, and ripple effects on the region

Geriatric oncology in resource-limited settings

Intra-arterial gemcitabine and IV gemcitabine/nab-paclitaxel show similar SAEs in locally advanced pancreatic cancer

Experiences of women caring for their husbands with cancer at the Cancer Diseases Hospital in Zambia

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer